Becton-Dickinson Medical Device Company Intelligence Report

Summary

Becton Dickinson and Company (BD), headquartered in Franklin Lakes, New Jersey, USA, manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. In fiscal 2004, BD reported revenue of US$4.9 billion, an increase of 11% over 2003, or by 6% excluding the effect of exchange rates.

BD's products are organised within three business segments; BD Medical, BD Biosciences and BD Diagnostics.

BD Medical is a world leader in providing safety-engineered injection, infusion and surgery devices. BD Medical's principal products include needles and syringes for medication delivery; IV catheters and infusion therapy products; insulin injection devices and blood glucose monitors for people with diabetes; surgical blades and regional anaesthesia needles; ophthalmic surgery devices; sharps disposal containers; and home healthcare products. In fiscal 2004, BD Medical's revenue increased to US$2.7 billion, a rise of 4% over the prior year excluding currency translation effects. BD Medical's operating income rose by 1.9% to US$566.6 million, despite the inclusion of US$45 million for the blood glucose test strip recall.

BD Diagnostics is a leading provider of products for the safe collection and transport of diagnostic specimens, and of instrumentation for quick, accurate analysis for a broad range of microbiology and infectious disease testing. BD Diagnostics' principal products and services are integrated systems for evacuated blood collection; an extensive line of safety-engineered specimen collection products and systems; plated media; automated blood culturing and molecular testing systems; microorganism identification and drug susceptibility systems; and healthcare consulting. In fiscal 2004, BD Diagnostics' revenue rose to US$1.5 billion, an increase of 7% excluding the effects of currency translation.

BD Biosciences is one of the world's largest businesses focused on bringing innovative research and clinical tools to life scientists and clinicians. Principal products in this business include fluorescence activated cell sorters, monoclonal antibodies and kits; reagent systems for life sciences research; products to aid in drug discovery and growth of tissue cells; and diagnostic assays. This profile does not cover BD's laboratory or research systems. In fiscal 2004, BD Biosciences had revenue of US$723 million, a rise of 9% over the prior year, excluding the impact of currency translation.

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Content